[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"castrate-resistance-prostate-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:castrate-resistance-prostate-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100587380","phase-2-stereotactic-body-radiotherapy-or-standard-of-care-for-prostate-oligoprogressive-cancer-100587380",false,"NCT06927635","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer","Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial","SECURE","Inclusion Criteria:\n\n* Age \\>18 years\n* Able to provide informed consent\n* Histologic diagnosis of prostate adenocarcinoma\n* Castrate Resistance Prostate Cancer\n* Radiographic evidence of \\\u003C10 sites of extra-cranial OP metastatic lesions\n* Receiving any line of ST for \\>3 months\n* All sites of OP disease are amenable to and can be safely treated with SBRT\n* ECOG performance status 0-3\n\nExclusion Criteria:\n\n* Evidence of spinal cord compression\n* Contraindication to radiotherapy","MALE","18 Years","100 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).",[28,29],"Castrate Resistance Prostate Cancer","OligoProgressive Metastatic Disease",[31,32],"systemic therapy","stereotactic body radiation therapy (SBRT)","RECRUITING","2025-08-29",{"date":36,"type":37},"2025-09-05","ACTUAL",{"date":39,"type":37},"2025-07-08",{"date":41,"type":22},"2030-06",{"name":43,"class":44},"University Health Network, Toronto","OTHER"]